Silverberg Bernstein Capital Management LLC Trims Stake in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Silverberg Bernstein Capital Management LLC reduced its holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 0.7% during the fourth quarter, Holdings Channel.com reports. The fund owned 20,129 shares of the medical equipment provider’s stock after selling 144 shares during the quarter. Lantheus accounts for 1.6% of Silverberg Bernstein Capital Management LLC’s investment portfolio, making the stock its 16th largest holding. Silverberg Bernstein Capital Management LLC’s holdings in Lantheus were worth $1,801,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of the business. Wilmington Savings Fund Society FSB purchased a new stake in Lantheus in the third quarter worth approximately $25,000. Signaturefd LLC boosted its stake in shares of Lantheus by 40.5% in the 3rd quarter. Signaturefd LLC now owns 319 shares of the medical equipment provider’s stock valued at $35,000 after purchasing an additional 92 shares in the last quarter. Nkcfo LLC purchased a new position in Lantheus in the 2nd quarter worth $47,000. UMB Bank n.a. grew its stake in shares of Lantheus by 42.1% during the third quarter. UMB Bank n.a. now owns 425 shares of the medical equipment provider’s stock valued at $47,000 after buying an additional 126 shares during the last quarter. Finally, Kathleen S. Wright Associates Inc. bought a new stake in shares of Lantheus in the 3rd quarter valued at about $51,000. Hedge funds and other institutional investors own 99.06% of the company’s stock.

Wall Street Analysts Forecast Growth

LNTH has been the subject of several recent research reports. The Goldman Sachs Group assumed coverage on Lantheus in a research report on Wednesday, December 18th. They issued a “buy” rating and a $143.00 price objective for the company. Truist Financial reiterated a “buy” rating and set a $120.00 price target (down from $135.00) on shares of Lantheus in a report on Friday, November 8th. JMP Securities reissued a “market outperform” rating and issued a $112.00 price target on shares of Lantheus in a report on Tuesday. Finally, StockNews.com lowered shares of Lantheus from a “buy” rating to a “hold” rating in a report on Thursday, November 21st. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $131.86.

Lantheus Trading Up 1.5 %

LNTH stock opened at $94.05 on Wednesday. Lantheus Holdings, Inc. has a 12-month low of $50.20 and a 12-month high of $126.89. The stock’s 50 day simple moving average is $89.53 and its 200 day simple moving average is $99.87. The stock has a market capitalization of $6.54 billion, a PE ratio of 15.65 and a beta of 0.46.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.